Releases

Current Releases

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in Asian patients with NSCLC Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover Oncothyreon reports third quarter 2009 financial results & provides product pipeline update view complete archive

02/09/10 13:29 ET Quotes Delayed 20 minutes.